SEC Form 4 · accession 0001185829-26-000001
Edgewise Therapeutics, Inc. · EWTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Koch
Officer — President and CEO · Director
Period of report
Aug 12, 2026
Accepted (ET)
Aug 14, 2026 · 4:52 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001710072
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 12, 2026 | M | 17,969 | $0.00 | A | 48,584 | D | |
| Common Stock | Aug 12, 2026 | M | 21,875 | $0.00 | A | 70,459 | D | |
| Common StockF1,F2 | Aug 12, 2026 | S | 8,782 | $43.6408 | D | 61,677 | D | |
| Common StockF1,F3 | Aug 12, 2026 | S | 8,276 | $43.6582 | D | 53,401 | D | |
| Common StockF1,F4 | Aug 12, 2026 | S | 913 | $44.33 | D | 52,488 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF5 | $0.00 | Aug 12, 2026 | M | 17,969 | D | — | Aug 12, 2034 | Common Stock | 17,969 | 35,938 | D |
| Restricted Stock UnitsF6 | $0.00 | Aug 12, 2026 | M | 21,875 | D | — | Aug 12, 2035 | Common Stock | 21,875 | 65,625 | D |
| Restricted Stock UnitsF7 | $0.00 | Aug 12, 2026 | A | 100,000 | A | — | Aug 12, 2036 | Common Stock | 100,000 | 100,000 | D |
| Stock Option (Right to Buy)F8 | $43.56 | Aug 12, 2026 | A | 200,000 | A | — | Aug 12, 2036 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
- F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $ 43.26 to $44.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.33 to $44.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
- F6Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
- F7Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
- F81/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.